Improved visual [123I]FP-CIT SPECT interpretation for evaluation of parkinsonism by visual rating of parametric distribution volume ratio images

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 3, 2011, Pages 301-309

  Meyer, P T ^a,b   Winz, O H ^b   Dafotakis, M ^b   Werner, C J ^b   Krohn, T ^b   Schafer W M ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Dopamine plasma membrane transport proteins; Parkinsonian disorders; Single photon emission computed tomography

Indexed keywords

IODINE 123;

ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL EVALUATION; DIAGNOSTIC ACCURACY; DISTRIBUTION VOLUME; DRUG UPTAKE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOLLOW UP; HUMAN; IMAGE ANALYSIS; PARKINSONISM; PUTAMEN; RECEIVER OPERATING CHARACTERISTIC; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREMOR;

AGED; BRAIN; CAUDATE NUCLEUS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; IODINE RADIOISOTOPES; MIDDLE AGED; OBSERVER VARIATION; PARKINSONIAN DISORDERS; PUTAMEN; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 79960995851     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A et al. N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)- tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994;37:1558-61. (Pubitemid 24195468)
2. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123) I-labelled dopamine D(2) transporter ligands. Eur J Nucl Med MoI Imaging 2002;29:BP30-5.
3. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305-13. (Pubitemid 46367938)
4. Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. J Nucl Med 1999;40:753-61. (Pubitemid 29210748)
5. Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 1996;37:1129-33. (Pubitemid 26329519)
6. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27:1533-9. (Pubitemid 47301451)
7. Meyer PT, Sattler B, Lincke T, Seese A, Sabri O. Investigating dopaminergic neurotransmission with 123I-FP-CIT SPECT: comparability of modern SPECT systems. J Nucl Med 2003;44:839-45. (Pubitemid 39655220)
8. Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med 2005;46:1109-18. (Pubitemid 43741072)
9. Koch W, Radau PE, Münzing W, Tatsch K. Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom. Eur J Nucl Med Mol Imaging 2006;33:495-502.
10. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503-10. (Pubitemid 30333223)
11. Catafau AM, Tolosa E; DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004;19:1175-82.
12. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 1993;13:24-42. (Pubitemid 23016600)
13. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998;39:1500-8. (Pubitemid 28459875)
14. Meyer IT, Sattler B, Winz OH, Fundke K, Oehlwein C, Kendziorra K et al. Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: a critical evaluation of the single-scan approach. Neuroimage 2008;42:548-58.
15. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med 1998;39:1143-8. (Pubitemid 28326141)
16. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114:2283-301.
17. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996;37:1760-5. (Pubitemid 26378356)
18. Eshuis SA, Maguire RP, Leenders KL, Jonkman S, Jager PL. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mol Imaging 2006;33:200-9. (Pubitemid 43152888)
19. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692-8. (Pubitemid 30479622)
20. Acton PD, Newberg A, Plössl K, Mozley PD. Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT. Phys Med Biol 2006;51:575-85. (Pubitemid 43139105)
21. Van Laere K, De Ceuninck L, Dom R, Van den Eynden J, Vanbilloen H, Cleynhens J et al. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging 2004;31:1119-27. (Pubitemid 39050179)
22. Messa C, Volonté MA, Fazio F, Zito F, Carpinelli A, d'Amico A et al. Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med 1998;25:1270-6. (Pubitemid 28446053)
23. Acton PD, Mozley PD, Kung HF. Logistic discriminant parametric mapping: a novel method for the pixel-based differential diagnosis of Parkinson's disease. Eur J Nucl Med 1999;26:1413-23. (Pubitemid 29515602)
24. Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients. J Nucl Med 2007;48:857-64. (Pubitemid 46909911)